The International Iberian Nanotechnology Laboratory \u2013 INL, its spin-off RUBYnanomed, (Braga, Portugal) a promising company in the field of liquid biopsy, and BioView Ltd., from Rehovot Israel (TASE:BIOV) a provider of automated cell imaging and analysis solutions, announce their collaboration for the development of a custom imaging solution to accelerate the deployment of their circulating tumour cell (CTC) technology in the clinic, in the framework of the CTC-OD project funded by \u201cla Caixa\u201d Foundation. <\/p>\n\n\n\n
The collaboration combines RUBYnanomed\u2019s technology, the RUBYchip\u2122 that provides highly efficient isolation of CTCs from blood samples of cancer patients, and BioView\u2019s Duet imaging and analysis system, which streamlines the otherwise challenging process of CTC detection and analysis. These CTCs are responsible of the metastasic process, and their analysis provides real-time information about cancer progression, enabling the prediction of disease aggressiveness and resistance to therapy. The combination of these two technologies provides an extraordinarily efficient, automated, standardized, high-throughput, high-capacity solution to study CTCs in the clinic. <\/p>\n\n\n\n
<\/p>
RUBYnanomed\u2019s Founders team and members of the Medical Devices Research Group at INL, commented: \u201cThe integration of BioView\u2019s imaging technology in our workflow for CTC analysis will help us to automatically classify cancer cells that are immobilized in our system. The automation enables an unprecedented sample-to-result turnaround from days to just a few hours, facilitating more frequent patient monitoring and stratification\u201d.<\/cite><\/blockquote>\n\n\n\n<\/p>\n\n\n\n
<\/p>
BioView Ltd. President and CEO, Dr. Alan Schwebel, commented:
“We are very excited to collaborate with INL and RUBYnanomed to help advance CTC S2A (sampleto-answer) solutions to the clinical laboratory. We believe that the integration of this cutting-edge enrichment technology and BioView\u2019s state-of-the \u2013art CTC imaging and analysis capabilities is an important milestone in our vison to standardize CTC Liquid Biopsy downstream analysis\u201d.
<\/cite><\/blockquote>\n\n\n\n* The combined imaging solution and the RUBYchipTM are currently used for research purposes only but, with the support of the CaixaImpulse program, we expect to start official clinical trials for regulatory approval in 2022.
**The project leading to these results has received funding and support from the \u201cla Caixa\u201d Foundation under CaixaImpulse Grant LCF\/TR\/CC20\/52480003.<\/p>\n\n\n\nAbout INL www.inl.int <\/a>
INL, the International Iberian Nanotechnology Laboratory, is the first, and so far the only, fully international research organization in Europe in the field of nanoscience and nanotechnology. INL is an international intergovernmental research organization (IGRO) with the mission to perform cutting-edge research and development in interdisciplinary nanotechnology and to function as an innovation integrator in multiple application domains. INL was created under an international legal framework similar to that of other International Research organizations like CERN, EMBL or ESA and with the aim to become a global centre of excellence in applied nanotechnology research. The centre provides a high-tech research environment to address major challenges of Nanotechnologies, in four main areas: Health, Safety in Environmental and Food control, Renewable Energy, Information and Communication Technologies. The Precise Personalised HealthTech Cluster of INL works at the interface between Engineering and Medicine, by developing novel nano-enabled Medical Technologies in collaboration with hospitals that can provide significant advantages for the prevention, earlier diagnosis, and personalized treatment of diseases. <\/p>\n\n\n\n